Gilead put profit ahead of hepatitis C patients -U.S. Senate report
December 01, 2015 at 13:17 PM EST
Dec 1 (Reuters) - U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences' new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines.